RETATRUTIDE
💬 Questions?
Have questions about Retatrutide or would like more information?
We’re happy to answer questions about our current inventory and provide additional information about our educational resources.
RETATRUTIDE (LY3437943) - CLINICAL RESEARCH DOSSIER
⚡ EXECUTIVE HIGHLIGHTS: THE METABOLIC BREAKTHROUGH OF THE DECADE
Are you ready to explore the future of metabolic medicine? Retatrutide represents a monumental leap forward in clinical research, outperforming existing treatments by targeting three separate nutrient-sensing pathways at once.
The 30% Weight Loss Milestone: Clinical data shows unprecedented weight reduction, with participants losing an average of up to 30.3% of their total body weight—numbers previously only achievable through major surgery.
Reversing Fatty Liver Disease: Driven by its unique glucagon activator, this molecule directly burns fat inside liver tissue, aiming to eliminate up to 80%+ of liver fat in record time.
Resolution of Sleep Apnea: Research shows a staggering 60% reduction in sleep apnea episodes, allowing many study participants to breathe freely without a CPAP machine.
Erasing Chronic Joint Pain: Patients suffering from severe knee osteoarthritis reported an incredible 75% drop in pain scores, with more than 1 in 8 becoming entirely pain-free.
High-Efficiency Diabetes Control: Delivers deep, rapid drops in blood sugar (HbA1c reductions up to 2.0%) alongside weight loss numbers never before seen in diabetic patients.
Ultimate Full-Body Protection: Active global trials are tracking its powerful ability to slash long-term risk for heart attacks, strokes, and kidney decline.
Intrigued by these unprecedented clinical outcomes? Read on to explore the deep scientific data, active Phase 3 clinical trials, and medical targets behind this investigative medical breakthrough.
COMPREHENSIVE RESEARCH INDICATIONS & CLINICAL TRIAL DIRECTORY
CHRONIC WEIGHT MANAGEMENT & OBESITY
Research Focus: Evaluating maximum weight reduction capacity, percentage of body fat lost, long-term weight maintenance, and the reversal of obesity-related comorbidities.
Key Phase 3 Program: TRIUMPH-1 (Master Protocol), TRIUMPH-2, and TRIUMPH-6 (Weight Maintenance Study).
Key Milestones: In the pivotal TRIUMPH-1 trial, the 12 mg maximum dose achieved an unprecedented average weight loss of 28.3% (70.3 lbs) at 80 weeks. In an extended 104-week tracking sub-group with severe obesity (BMI of 35 or higher), weight loss continued downward to an average of 30.3% (85.0 lbs).
TYPE 2 DIABETES MELLITUS (T2DM)
Research Focus: Evaluating glycemic control, hemoglobin A1c (HbA1c) lowering efficacy, improvements in fasting glucose, and changes in beta-cell function (insulin secretion).
Key Phase 3 Program: TRANSCEND-T2D-1 and TRANSCEND-T2D-2.
Key Milestones: Topline data from the TRANSCEND-T2D-1 trial demonstrated an average HbA1c reduction between 1.7% and 2.0% over 40 weeks, while simultaneously facilitating a 16.8% body weight loss in patients with poorly controlled type 2 diabetes.
METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD / MASH)
Research Focus: Tracking the resolution of "fatty liver" by measuring changes in liver fat content via MRI-PDFF scans, lowering liver enzymes, and investigating if the triple-agonist action can prevent or reverse liver fibrosis (scarring).
Key Phase 3 Program: Phase 3 Multi-Agent MASLD Master Protocol (with a dedicated retatrutide arm).
Scientific Rationale: The inclusion of the "Glucagon" receptor target specifically increases fat metabolism (lipolysis) directly inside liver tissue, a mechanism missing from single GLP-1 medications.
OBSTRUCTIVE SLEEP APNEA (OSA)
Research Focus: Measuring the reduction of airway collapses and breathing interruptions per hour during sleep, with the goal of reducing or eliminating the medical necessity for CPAP machines.
Key Phase 3 Program: TRIUMPH-1 (Nested Sleep Apnea Protocol).
Key Milestones: Dedicated data presented at the American Diabetes Association (ADA) Scientific Sessions revealed that retatrutide delivered a 60.6% reduction in the Apnea-Hypopnea Index (AHI) from a severe baseline, essentially resolving sleep apnea events for many participants.
CHRONIC OSTEOARTHRITIS PAIN (KNEE & LOW BACK)
Research Focus: Investigating if rapid systemic weight reduction paired with anti-inflammatory mechanisms can structurally reduce mechanical joint stress, decrease chronic pain scores, and restore physical function.
Key Phase 3 Program: TRIUMPH-4 (Knee Osteoarthritis) and TRIUMPH-7 (Chronic Low Back Pain).
Key Milestones: In the 68-week TRIUMPH-4 trial, patients achieved a 28.7% average weight loss alongside a massive 75.8% improvement in knee osteoarthritis pain scores, with more than 1 in 8 patients reporting becoming completely pain-free.
CARDIOVASCULAR OUTCOMES (HEART HEALTH)
Research Focus: Determining if retatrutide lowers the risk of Major Adverse Cardiovascular Events (MACE) such as heart attacks, strokes, or cardiovascular death in high-risk patients. It also tracks improvements in blood pressure, systemic inflammation markers (like hs-CRP), and circulating lipid panels (triglycerides and non-HDL cholesterol).
Key Phase 3 Program: TRIUMPH-3 (Obesity and Cardiovascular Disease) and TRIUMPH-Outcomes.
Key Milestones: TRIUMPH-3 has completed primary data collection, while the massive, multi-year TRIUMPH-Outcomes trial (~10,000 global participants) is tracking long-term hard endpoints through 2027 and beyond.
CHRONIC KIDNEY DISEASE (RENAL PROTECTION)
Research Focus: Measuring changes in kidney function, evaluating the reduction of albuminuria (protein in the urine), and assessing if the drug slows the progression of chronic kidney disease in adults living with obesity and established cardiorenal risks.
Key Phase 3 Program: TRIUMPH-Outcomes (Dual Cardiovascular and Renal Endpoint Protocol).